Outlook Therapeutics’ Bevacizumab Proves Non-inferior to Ranibizumab in 12-Week Trial
After failing to show non-inferiority to ranibizumab at 8 weeks late last year, ONS-5010’s new 12-week data strengthens the case…
One Day, Three IRD Gene Therapy Triumphs
January 8, 2025, was no ordinary day in the world of gene therapy for inherited retinal diseases (IRDs)—it was a…
popular posts
latest posts
